
Novavax Highlights Technology Platform and Matrix-M® Adjuvant Potential at World Vaccine Congress

We were thrilled to participate in the recent World Vaccine Congress, a premier event bringing together global leaders in vaccine development and innovation. It provided an excellent platform for Novavax to engage with industry and healthcare community at large.

A key highlight of our participation was a presentation by Novavax's Executive Vice President, Head of Research and Development, Ruxandra Draghia-Akli, MD, PhD. Dr. Draghia-Akli presented on "The potential of Novavax's technology platform and Matrix-M® adjuvant," delving into the science that underpins our vaccine candidates.

We believe our platform offers significant advantages in developing effective vaccines against both established and emerging diseases and can help address pressing global health challenges.

For those who couldn't attend or would like to review, find the presentation [here](#).

Our presence at the World Vaccine Congress reaffirms Novavax's commitment to advancing vaccine science through innovation and partnerships. We look forward to continuing these important conversations and collaborations within the global health community.

Novavax team at World Vaccine Congress